Bruce, Matthew R. http://orcid.org/0000-0002-6943-1410
Jones, Karen L.
Vernon, Anthony C. http://orcid.org/0000-0001-7305-1069
Silverman, Jill L. http://orcid.org/0000-0001-9357-5476
Crawley, Jacqueline N. http://orcid.org/0000-0002-1224-995X
Ellegood, Jacob http://orcid.org/0000-0003-1504-3321
Lerch, Jason P.
Van de Water, Judy http://orcid.org/0000-0003-1193-5875
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Environmental Health Sciences
RCUK | Medical Research Council (MR/N026063/1)
Ontario Brain Institute
Gouvernement du Canada | Canadian Institutes of Health Research
Fondation Brain Canada
Article History
Received: 1 March 2021
Revised: 15 June 2021
Accepted: 24 June 2021
First Online: 21 July 2021
Competing interests
: Van de Water has a patent application involving the MAR ASD peptides described herein and has a UC Davis-based startup company focusing on the development of the MAR-ASD autoantibody profile as a risk assessment for a child developing ASD. All other authors have no conflicts of interest to declare.